A foreign medical device manufacturer had completed product development, appointed an Indian distributor and scheduled its first commercial shipment. The device was already marketed overseas, and the management assumed that an ISO 13485 certificate and foreign regulatory approval would be sufficient to begin importing into India.
The problem surfaced shortly before shipment. The product model mentioned in the commercial documents did not match the model covered by the Free Sale Certificate. The intended use stated in the Indian application differed from the Device Master File, and the appointed importer did not have the correct authorisation to act as the manufacturer’s Indian authorised agent.
The shipment had to be postponed. Product launch commitments were missed, distributor inventory planning was disrupted, and the manufacturer had to rebuild part of its CDSCO submission.
This is a common medical device market-entry problem. The delay is rarely caused by a single missing certificate. It usually results from incorrect device classification, an unsuitable authorised agent, inconsistent technical documentation or failure to understand the Form MD-14 and Form MD-15 approval sequence.
A competent CDSCO Medical Device Import Licence Consultant in India helps businesses evaluate the complete regulatory pathway before products are shipped, commercial commitments are signed or labels are finalised.
Medical devices imported for commercial sale in India are regulated under the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017. CDSCO acts as the Central Licensing Authority for the grant of import licences.
Under Rule 34 of the Medical Devices Rules, an eligible Indian authorised agent must submit the application in Form MD-14 through the identified online system. After technical evaluation and any inspection considered necessary, CDSCO may grant the import licence in Form MD-15.
The November 2025 CDSCO circular also clarified that import licences for all risk classes of medical devices are issued by the Central Licensing Authority. The applicant must separately hold the applicable licence or registration for the sale and distribution of medical devices in India.
Importers should therefore avoid treating CDSCO approval as a documentation exercise completed after the purchase order. Regulatory planning should begin before:
| Regulation or provision | Main requirement | Applicable to | Important timeline | Business risk |
|---|---|---|---|---|
| Drugs and Cosmetics Act, 1940 | Governing legislation for regulated medical devices | Manufacturers, importers and authorised agents | Continuous compliance | Prosecution and enforcement action |
| Medical Devices Rules, 2017 | Classification, licensing, documentation and post-market compliance | Medical devices and IVDs | Before commercial import | Application rejection or shipment hold |
| Rule 34 | Application in Form MD-14 through an authorised agent | Imported licensed medical devices | Before import | No MD-15 licence |
| Rule 35 | Overseas manufacturing-site inspection where directed | Foreign manufacturing sites | During evaluation | Extended approval timeline |
| Rule 36 | Grant or rejection of import licence in Form MD-15 | Eligible MD-14 applications | Up to 9 months | Delayed market entry |
| Rule 37 | Retention of MD-15 licence | Existing licence holders | Every 5 years | Deemed cancellation |
| Rule 38 | Post-approval conditions and change control | Authorised agents and overseas manufacturers | 15, 30 or 60 days depending on event | Recall, suspension or cancellation |
| Rule 43A | Suspension and cancellation powers | Non-compliant licence holders | After regulatory proceedings | Stop-import, stop-sale or destruction order |
The framework is not based only on product classification. CDSCO examines the manufacturer, manufacturing site, authorised agent, quality system, technical file, regulatory history, clinical evidence, labels and post-market controls.
A technically acceptable product may still face an objection where its Power of Attorney, Free Sale Certificate, model list or labelling documents are inconsistent.
India follows a risk-based classification system consisting of Class A, Class B, Class C and Class D devices.
Class A represents the lowest-risk category, while Class D covers the highest-risk products. Classification depends on factors such as invasiveness, duration of contact, intended use, implantability, active function and the potential consequence of device failure.
Most commercially imported Class A, B, C and D devices require an application in Form MD-14 and an import licence in Form MD-15. However, an important exception applies to Class A devices that are both non-sterile and non-measuring.
These Class A non-sterile and non-measuring devices are exempt from Chapters IV, V, VII, VIII and XI of the Medical Devices Rules, subject to registration under Chapter IIIB. They do not follow the normal MD-14 to MD-15 route.
| Device category | Normal import pathway |
|---|---|
| Class A, non-sterile and non-measuring | Chapter IIIB registration |
| Class A sterile or measuring | Form MD-14 followed by Form MD-15 |
| Class B | Form MD-14 followed by Form MD-15 |
| Class C | Form MD-14 followed by Form MD-15 |
| Class D | Form MD-14 followed by Form MD-15 |
| Investigational medical device | Prior Form MD-27 permission, followed by the applicable import route |
| New in vitro diagnostic medical device | Prior Form MD-29 permission, followed by the applicable import route |
| Device imported only for testing, evaluation or demonstration | Form MD-16 followed by Form MD-17 |
Classification should be confirmed against the current CDSCO classification list and the precise intended use. A classification based only on the product name may be unreliable because devices with similar names can fall into different classes depending on their clinical function.
A foreign manufacturer cannot ordinarily submit the MD-14 application directly without an eligible Indian authorised agent.
Under Rule 34, the authorised agent must hold an appropriate manufacturing licence, wholesale licence for sale or distribution, or a registration certificate in Form MD-42, as applicable. The agent submits the application and acts as the foreign manufacturer’s official regulatory representative in India.
The relationship must be supported by a Power of Attorney prepared in accordance with Part I of the Fourth Schedule. The document must be authenticated in India by a Magistrate of First Class, by the Indian Embassy in the country of origin or by an equivalent authority through apostille.
The authorised agent is responsible for more than portal access. Its role extends to:
Selecting an agent only because it can import or distribute the product may create long-term dependence and regulatory risk. The Power of Attorney, commercial distribution agreement and control over the CDSCO licence should be reviewed as separate matters.
Form MD-14 is the application submitted for the grant of an import licence. Form MD-15 is the licence issued by CDSCO after the application has been evaluated and accepted.
The application covers the overseas manufacturer, actual manufacturing site, authorised agent and the medical devices proposed for import. Additional devices manufactured at the same licensed site require an endorsement application. A separate application may be needed where an additional manufacturing site is involved.
Rule 34 also requires the applicant to inform CDSCO of changes in the submitted documents occurring before the grant of the licence. Failure to update the authority can make the application technically inaccurate even when the original documents were correct on the filing date.
The current CDSCO workflow describes the standard route as:
CDSCO has also introduced a separate portal provision for a subsequent importer. This route became functional from 11 September 2025 for medical devices and IVDs already approved for another authorised agent, provided the legal and actual manufacturing site remains the same.
The MD-15 checklist separates the submission into legal, regulatory, quality and technical evidence. Preparing a valid checklist is not enough. The content of every certificate must agree with the application.
The principal legal documents generally include:
The authorised-agent address, manufacturer name and manufacturing-site details must remain consistent across the Power of Attorney, quality certificate, Free Sale Certificate, Plant Master File and application.
CDSCO may require:
A Free Sale Certificate should cover the exact device, model, variant and manufacturing site included in the Indian application. Broad commercial catalogues or self-declarations may not replace an approval issued by the competent regulatory authority.
The official checklist requires a Quality Management System certificate for the actual manufacturing site, together with a Plant Master File and Device Master File prepared under the Fourth Schedule.
The Device Master File normally covers:
The checklist specifically refers to batch-release certificates or Certificates of Analysis for a minimum of three consecutive batches, or a software-version release certificate where applicable.
| Step | Authority or form | Regulatory position | Key documents | Main delay risk |
|---|---|---|---|---|
| 1 | Internal classification review | Before application | Intended use, design and classification justification | Wrong device class |
| 2 | Indian authorised-agent appointment | Before MD-14 | Power of Attorney and agent licence | Ineligible agent |
| 3 | Form MD-14 submission | CDSCO online system | Legal, regulatory, PMF and DMF documents | Incomplete application |
| 4 | Technical scrutiny | CDSCO | Classification, quality, safety and performance evidence | Deficiency queries |
| 5 | Overseas inspection, if directed | CDSCO or delegated body | QMS and manufacturing-site records | Inspection scheduling |
| 6 | Grant or rejection | Form MD-15 | Complete evaluated dossier | Up to 9-month statutory period |
| 7 | Sale and distribution readiness | Relevant licensing authority | Wholesale or Form MD-42 compliance | Product cannot be legally distributed |
| 8 | Post-approval lifecycle management | CDSCO | Vigilance, changes and retention records | Suspension or cancellation |
Rule 36 allows CDSCO to grant or reject an import licence within nine months from the application date. Where the application is rejected, the applicant may appeal to the Central Government within 45 days. The Government may pass an order within 90 days from the appeal date.
The nine-month period is the regulatory timeline, not a guaranteed processing duration for every application. A complete submission may progress sooner, while technical deficiencies, clinical evidence requirements or overseas inspection can extend the practical market-entry schedule.
Businesses should also allocate time for:
The country in which the medical device is approved can affect the Indian clinical evidence pathway.
Rule 36 provides that where a Free Sale Certificate has been issued by the competent authority of Australia, Canada, Japan, an EU country or the United States, an import licence may be granted without conducting a clinical investigation in India.
For devices from other jurisdictions, the pathway depends on risk classification. A Class C or Class D device may require its safety and effectiveness to be established through a clinical investigation in India. Class A and Class B devices may rely on published safety and performance data or clinical investigation from the country of origin, together with a Free Sale Certificate from that country.
An investigational medical device that does not have an approved predicate pathway requires prior permission in Form MD-27. A new IVD requires prior permission in Form MD-29 before the import licence can be granted.
Foreign approval should therefore be reviewed for:
The proposed label and instructions for use form part of the Device Master File. The approved intended use, model, manufacturer, importer or authorised-agent particulars and other applicable information must remain consistent with the licence.
Imported devices should not be shipped merely because the global label has been approved in another country. India-specific labelling requirements must be mapped before commercial dispatch.
Particular attention should be given to:
Labelling inconsistency can create problems during CDSCO scrutiny, customs clearance, market inspection and complaint investigation.
Receiving Form MD-15 is not the end of regulatory responsibility. Rule 38 creates continuing obligations for the licence holder and authorised agent.
Any overseas administrative action arising from adverse reaction, market withdrawal, regulatory restriction, authorisation cancellation or a declaration that the device is not of standard quality must be reported to CDSCO immediately and, in all circumstances, within 15 days. Dispatch and marketing must be stopped immediately in the circumstances specified by the rule.
The principal change-control timelines are:
| Compliance event | Required action | Timeline |
|---|---|---|
| Foreign regulatory action or market withdrawal | Inform CDSCO and take applicable stop-market action | Within 15 days |
| Major change | Obtain prior CDSCO approval | Decision contemplated within 60 days |
| Minor change | Inform CDSCO after implementation | Within 30 days |
| Change in constitution | Inform CDSCO | Within 30 days |
| Fresh application after change in constitution | Submit under Rule 34 | Within 180 days |
| MD-15 retention | Submit retention compliance | After every 5 years |
Rule 37 provides that an MD-15 licence remains valid in perpetuity unless cancelled or surrendered, subject to payment of the prescribed retention fee after every five years for each overseas manufacturing site and licensed medical device.
Where the retention requirement is missed, CDSCO may allow payment within a further 90 days with a late fee calculated at 2% per month. Failure to deposit the amount within that period results in the licence being deemed cancelled.
An incorrect medical device import application can cause consequences beyond portal queries.
Where an imported device does not comply with the Act, the rules or licence conditions, CDSCO can restrict sale, direct recall or take action against the licence. Under Rule 43A, the Central Licensing Authority may suspend or cancel the licence, stop import, sale or distribution and order destruction of the device or stock after following the prescribed process.
Practical business risks include:
These risks explain why shipment planning should begin only after confirming that the licensed device name, model, site and Indian label match the commercial consignment.
An overseas manufacturer planned to import five versions of a diagnostic device under one application. The products shared a brand name and similar external design, so the Indian importer treated them as one device family.
During evaluation, CDSCO observed that two versions had different intended uses, another used different software logic and one model had a separate sterilisation process. The original grouping justification did not adequately establish that all five devices could be covered together.
The applicant had to revise the grouping strategy, update the Device Master File and align the Free Sale Certificate, labels and verification data with the new product structure.
The delay could have been reduced through a pre-submission assessment covering:
The lesson is that a commercial product family is not automatically a regulatory device family.
A CDSCO Medical Device Import Licence Consultant in India should begin by determining the correct route, not by immediately uploading documents.
The first stage is regulatory assessment. This includes confirming whether the product is a medical device, identifying the applicable risk class and determining whether the Class A non-sterile and non-measuring exemption applies.
The second stage is legal and technical gap analysis. Every document is checked for consistency across the manufacturer name, site, product name, intended use, models, shelf life and regulatory approval.
The third stage is dossier preparation and submission. The consultant coordinates the Power of Attorney, Plant Master File, Device Master File, Essential Principles checklist, risk-management records, clinical evidence and label documents before Form MD-14 is submitted.
The final stage is lifecycle support, including:
The objective is not merely to secure an approval. It is to create a defensible regulatory file that remains usable during customs clearance, market inspection, product expansion and licence retention.
The CDSCO medical device import licence process requires coordination between the foreign manufacturer, Indian authorised agent, importer, distributor and technical team.
The application must establish that the device is correctly classified, manufactured under an acceptable quality system, supported by suitable safety and performance evidence and represented by an eligible authorised agent in India.
A weak submission can delay product launch for several months. In comparison, early classification, document reconciliation and label review involve a relatively small effort before commercial import begins.
Working with a CDSCO Medical Device Import Licence Consultant in India can help manufacturers and importers manage Form MD-14 filing, Form MD-15 approval, technical documentation, portal responses and post-approval compliance through one structured process.
The strongest strategy is to complete the regulatory review before appointing distributors, printing labels or dispatching the first shipment.
📞 +91 78350 06182
📧 wecare@greenpermits.in
👉 Book a Consultation with Green Permits
Form MD-14 is the application submitted by an eligible Indian authorised agent to CDSCO for the grant of a medical device import licence.
Form MD-15 is the import licence issued by CDSCO after evaluation of the application, technical documents and inspection report, where an inspection is conducted.
Rule 36 provides a period of up to nine months from the application date for grant or rejection. Actual processing depends on application completeness, technical queries and inspection requirements.
No. The licence remains valid in perpetuity unless cancelled or surrendered, subject to completion of the retention requirement after every five years.
